Oncology Fellows
Vol. 17/No. 3
Vol.17/No.4
Volume: 17
Issue: 4
Vol. 17/No. 2
Volume: 17
Issue: 2
Vol. 17/No. 1
Volume: 17
Issue: 1
Vol. 16/No. 4
Volume: 16
Issue: 4
Vol. 16/No. 3
Volume: 16
Issue: 3
Vol. 16/No. 2
Volume: 16
Issue: 2
Vol. 16/No. 1
Volume: 16
Issue: 1
Vol. 15/No. 4
Volume: 15
Issue: 4
Vol. 15/No. 3
Volume: 15
Vol. 15/No. 2
Volume: 14
Vol. 15/No. 1
Volume: 15
Issue: 1
Vol. 14/No. 4
Volume: 14
Issue: 4
Vol. 14/No. 3
Volume: 14
Issue: 3
Vol. 14/No. 2
Volume: 14
Issue: 2
Vol. 14/No. 1
Volume: 14
Issue: 1
Vol. 13/No. 4
Volume: 13
Issue: 4
Vol. 13/No. 3
Volume: 13
Issue: 3
Vol. 13/No. 2
Volume: 13
Issue: 2
Vol. 13/No. 1
Volume: 13
Issue: 1
December 2020
Volume: 12
Issue: 4
September 2020
Volume: 1
Issue: 1
June 2020
Volume: 12
Issue: 2
March 2020
Volume: 12
Issue: 1
December 2019
Volume: 11
Issue: 3
September 2019
Volume: 11
Issue: 3
March 2019
Volume: 11
Issue: 1
June 2019
Volume: 11
Issue: 2
December 2018
Volume: 10
Issue: 4
September 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5